Literature DB >> 26163047

Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era.

W-C Lee1, C-F Lee2, C-H Cheng2, T-J Wu2, H-S Chou2, T-H Wu2, R-S Soong2, K-M Chan2, M-C Yu2, M-F Chen2.   

Abstract

AIMS: Surgical treatment for early-stage hepatocellular carcinoma (HCC) is toward transplantation. However, liver resection remains the major surgical treatment for HCC in Asia. This study is to examine the results of liver resection when liver transplantation became an option of treatment for early-stage HCC.
METHODS: In this retrospective cohort study, 1639 patients with resectable HCC were reviewed and divided into two groups. In the 1st period (2002-2005), all 679 patients received liver resection. In the 2nd period (2006-2010), 916 patients had liver resection and 44 patients jointed liver transplantation program. The results of treatment in these two periods were analyzed.
RESULTS: The characteristics of tumors were the most important factors of tumor recurrence after liver resection. Liver function reserve, characteristics of tumors, and surgeons' endeavor were all independent factors for overall survival after liver resection. When the patients with oligo-nodular tumors or portal hypertension with low platelet count had liver transplantation rather than liver resection in the 2nd period, the survival rates in the 2nd period were improved. When the patients in the 1st period with low platelet count (≤105 × 10(3)/uL) were subtracted, the 5-year survival rate of the patients with one-segmentectomy for small-sized HCC in the 1st period was similar to those in the 2nd period and transplant patients.
CONCLUSIONS: The outcomes of liver resection were improved while liver transplantation was performed for the patients with suspicious portal hypertension. Platelet count, 105 × 10(3)/uL, could be a watershed for early stage HCC patients to undergo liver resection or liver transplantation.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Liver transplantation; Outcomes; Platelet; Portal hypertension

Mesh:

Year:  2015        PMID: 26163047     DOI: 10.1016/j.ejso.2015.05.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

1.  Value of alpha-fetoprotein in hepatocellular carcinoma.

Authors:  Wei-Chen Lee
Journal:  Transl Gastroenterol Hepatol       Date:  2021-10-25

2.  Circular RNA 0006602 in plasma exosomes: a new potential diagnostic biomarker for hepatocellular carcinoma.

Authors:  Sen Guo; Chunxiao Hu; Xiangyu Zhai; Dong Sun
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Liver resection for early hepatocellular cancer: Comparison of centers in 3 different countries.

Authors:  Linda L Wong; Brenda Y Hernandez; Yurii B Shvetsov; Yoichi Kawano; Zhao-You Tang; Jun-Fang Ji
Journal:  World J Hepatol       Date:  2016-11-08

Review 4.  From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.

Authors:  Dimitrios Dimitroulis; Christos Damaskos; Serena Valsami; Spyridon Davakis; Nikolaos Garmpis; Eleftherios Spartalis; Antonios Athanasiou; Demetrios Moris; Stratigoula Sakellariou; Stylianos Kykalos; Gerasimos Tsourouflis; Anna Garmpi; Ioanna Delladetsima; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

5.  Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.

Authors:  Wei-Chen Lee; Hong-Shiue Chou; Ting-Jung Wu; Chen-Fang Lee; Pao-Yueh Hsu; Hsiu-Ying Hsu; Tsung-Han Wu; Kun-Ming Chan
Journal:  Clin Proteomics       Date:  2017-08-02       Impact factor: 3.988

6.  Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Wei-Chen Lee; Yu-Chao Wang; Chih-Hsien Cheng; Tsung-Han Wu; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

7.  Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan.

Authors:  Kun-Ming Chan; Tsung-Han Wu; Chih-Hsien Cheng; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Wei-Chen Lee
Journal:  Cancer Manag Res       Date:  2019-01-22       Impact factor: 3.989

8.  LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3.

Authors:  Peipei Fang; Luxia Xiang; Weilai Chen; Shaoxun Li; Shanshan Huang; Jie Li; Lu Zhuge; Lingxiang Jin; Wenke Feng; Yiping Chen; Chenwei Pan
Journal:  Innate Immun       Date:  2019-02       Impact factor: 2.680

9.  A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells.

Authors:  Lili Cao; Lijun Zhang; Xiang Zhao; Ye Zhang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

10.  Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.

Authors:  Kun-Ming Chan; Tsung-Han Wu; Chih-Hsien Cheng; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Wei-Chen Lee
Journal:  Biomed J       Date:  2019-10-29       Impact factor: 4.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.